F. Novelli, F. Sparatore / Il Farmaco 57 (2002) 871Á
/882
881
[2] S.D. Wyrick, R.G. Booth, Progress in s receptor research, Drugs
Fut. 20 (1995) 1033Á1044.
[3] B.J. Vilner, C.S. John, W.D. Bowen, Sigma-1 and sigma-2
acologica di ammido derivati 3-metil-3,4-diidrobenzo- e pirido-
1,2,4-triazin-3-acetici, Farmaco 44 (1989) 279Á301.
[21] F. Novelli, F. Sparatore, Preparation and pharmacological
/
/
activities of spiro[3,4-dihydro-6/7-R-1,2,4-benzotriazine-3,4?-(1?-
receptors are expressed in a wide variety of human and rodent
substituted)piperidines], Farmaco 51 (1996) 541Á550.
/
tumor cell lines, Cancer Res. 55 (1995) 408Á413.
/
[22] F. Novelli, F. Sparatore, Synthesis and preliminary pharmacolo-
[4] P.J. Gilligan, G.A. Cain, T.E. Christos, L. Cook, S. Drummond,
A.L. Johnson, A.A. Kergayl, J.F. Mc Elroy, K.W. Rohrbach,
W.K. Schmidt, S.W. Tam, Novel piperidine s receptor ligands as
gical evaluation of 3-[2-(1-arylpiperazin-4-yl)ethyl]-3,4-dihydro-3-
methyl-6-R-1,2,4-benzotriazines, Farmaco 51 (1996) 551Á558.
/
[23] (a) J.R. Geigy A.-G., Preparation of piperidine derivatives having
tranquilizing properties, Belg. Pat. 660,763 (1965);
(b) J.R. Geigy A.-G., Chem. Abstr. 64 (1966) 17552e.
[24] (a) J. Kenji, J. Kanji, K. Masumi, M. Norihide, T. Noboru, M.
Takashi, U. Ikuo, 4-Piperidinol derivatives, Japan Kokai 76-
118,769 (1976);
potential antipsychotic drugs, J. Med. Chem. 35 (1992) 4344Á
/
4361.
[5] X. Guitart, X. Codony, M. Ballarin, A. Dordal, A.J. Farre´, E-
5842: a new potent and preferential sigma ligand. Pharmacologi-
cal preclinical profile, CNS Drug Rev. 4 (1998) 201Á224.
/
[6] B. Gronier, G. Debonnel, Involvement of s receptors in the
modulation of the glutamatergic/NMDA neurotrasmission in the
(b) J. Kenji, J. Kanji, K. Masumi, M. Norihide, T. Noboru, M.
Takashi, U. Ikuo, Chem. Abstr. 86 (1977) 171263t.
[25] C. Schopf, G. Lehmann, Die Synthese des Tropinons, Pseudo-
¨
dopaminergic system, Eur. J. Pharmacol. 368 (1999) 183Á186.
/
[7] K.A. Mc Cracken, W.D. Bowen, B.R. de Costa, R.R. Matsu-
moto, Two novel s receptor ligands, BD1047 and LR172,
attenuate cocaine-induced toxicity and locomotor activity, Eur.
pelletierins, Lobelanins und verwandter Alkaloide unter physio-
logischen Bedingungen, Annalen 518 (1935) 1Á37.
/
[26] G.F. Costello, R. James, J.S. Show, A.M. Slater, N.C.J. Stutch-
bury, 2-(3,4-Dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-
substituted-ethyl]acetamides: the use of conformational analysis
in the development of a novel series of potent opioid k agents, J.
J. Pharmacol. 370 (1999) 225Á
[8] F.F. Moebius, J. Striessnig, H. Glossman, The mistery of sigma
receptors: new family member reveal role in cholesterol
synthesis, Trends Pharmacol. Sci. 18 (1997) 67Á70.
/
232.
a
/
Med. Chem. 34 (1991) 181Á
[27] (a) I. Guareschi, Sulla triacetonammina e suoi derivati alchilici,
Atti R. Accad. Sci. Torino (1894) 680Á692;
(b) I. Guareschi, Ber. Referate 28 (1895) 160Á
[28] A.K. Macbeth, J.R. Price, The absorption spectra of 1,2,3-
benzotriazoles, J. Chem. Soc. (1936) 111Á119.
[29] D. Dal Monte, A. Mangini, F. Montanari, Ricerche sugli
eterocicli*Nota VII*Spettri di assorbimento nel vicino UV di
N-ossidi della serie triazolica e basi eterocicliche, Gazz. Chim.
Ital. 88 (1958) 1035Á1062.
/189.
[9] F. Berardi, S. Ferorelli, N.A. Colabufo, M. Leopoldo, R.
Perrone, V. Tortorella, A multireceptorial binding reinvestigation
on an extended class of s ligands: N-[v-(Indan-1-yl and tetralin-
1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affi-
nities towards s1 and EBP sites, Biorg. Med. Chem. 9 (2001)
/
/161.
/
1325Á1335.
/
[10] C.S. John, B.B. Lim, B.J. Vilner, B.C. Geyer, W.D. Bowen,
Substituted halogenated arylsulfonamides: a new class of s
receptor binding tumor imaging agents, J. Med. Chem. 41
/
/
/
(1998) 2445Á2450.
/
[30] (a) F. Savelli, G. Cordella, F. Sparatore, Derivati benzo- e
[11] K.T. Wheeler, L.M. Wang, C.A. Wallen, S.R. Childers, J.M.
naftotriazolici quali potenziali antineoplastici, Studi. Sassaresi.
Cline, P.C. Keng, R.H. Mach, Sigma-2 receptors as a biomarker
60 (1982) 345Á348;
/
of proliferation in solid tumor, Br. J. Cancer. 82 (2000) 1223Á
/
(b) F. Savelli, G. Cordella, F. Sparatore, Chem. Abstr. 101 (1984)
90839m.
[31] W.D. Bowen, B.R. de Costa, S.B. Hellewell, M. Walker, K.C.
1232.
[12] R.A. Glennon, S.Y. Ablordeppey, A.M. Ismaill, M.B. El-Ash-
many, J.B. Fisher, K.B. Howie, Structural features important for
Rice, [3H]-(ꢁ
/
)pentazocine: a potent and highly selective benzo-
morphan-based probe for sigma-1 receptors, Mol. Neuropharma-
col. 3 (1993) 117Á126.
s1 receptor binding, J. Med. Chem. 37 (1994) 1214Á1219.
/
[13] S.Y. Ablordeppey, J.B. Fisher, R.A. Glennon, Is a nitrogen atom
/
an important pharmacophoric element in sigma ligand binding?,
[32] K. Hashimoto, E.D. London, Further characterization of
[3H]ifenprodil binding to sigma receptors in rat brain, Eur. J.
Biorg. Med. Chem. 8 (2000) 2105Á2111.
/
[14] W. Quaglia, M. Giannella, A. Piergentili, M. Pigini, L. Brasili, R.
Di Toro, L. Rossetti, S. Spampinato, C. Melchiorre, 1-Benzyl-3,4-
dihydrospiro[2H-1-benzothiopyran-2,4?-piperidine] (spipethiane),
a potent and highly selective s1 ligands, J. Med. Chem. 41 (1998)
Pharmacol. 236 (1993) 159Á163.
[33] J.E. Leysen, C.J.E. Niemegeers, J.M. Van Nueten, P.M. Laduron,
[3H]Ketanserin, a selective [3H]ligand for serotonin 2 receptor
/
binding sites, Mol. Pharmacol. 21 (1982) 301Á314.
/
1557Á1560.
/
[34] D.K. Grandy, M.A. Marchionni, H. Makam, R.E. Stofko, M.
Alfano, L. Frothingham, J.B. Fisher, K.J. Burke-Howie, J.R.
Bunzow, A.C. Seiver, O. Civelli, Cloning of the cDNA and gene
for a human D2 dopamine receptor, Proc. Natl. Acad. Sci. USA.
[15] F. Berardi, S. Santoro, P. Perrone, V. Tortorella, S. Govoni, L.
Lucchi, N-[v-(Tetralin-1-yl)alkyl]derivatives of 3,3-dimethylpi-
peridine are highly potent and selective s1 or s2 ligands, J.
Med. Chem. 41 (1998) 3940Á3947.
/
86 (1989) 9762Á9766.
/
[16] A. Marrazzo, O. Prezzavento, L. Pasquinucci, F. Vittorio, G.
[35] G. Hayes, T.J. Biden, L.A. Selbie, J. Shine, Structural subtypes of
the dopamine D2 receptor are functionally distinct: expression of
the clone D2A and D2B subtypes in a heterologous cell line, Mol.
Ronsisvalle, Synthesis and pharmacological evaluation of potent
and enantioselective s1 and s2 ligands, Farmaco 56 (2001) 181Á
/
189.
[17] P.J. Gilligan, A.A. Kergayl, B.M. Lewis, J.F. Mc Elroy,
Endocr. 6 (1992) 920Á926.
[36] G.L. Ellman, K.D. Courtney, A. Andres, Jr., R.M. Featherstone,
/
Piperidinyl tetralin s ligands, J. Med. Chem. 37 (1994) 364Á
[18] R. Cerri, A. Boido, F. Sparatore, Preparazione di 3,4-diidro-1,2,4-
benzotriazine 3,3-disostituite, Farmaco, Ed. Sci. 35 (1980) 715Á
724.
[19] F. Sparatore, R. Cerri, G. Delrio, R.K. Rastogi, Derivati 3,4-
/
370.
A new and rapid colorimetric determination of acetylcholinester-
ase activity, Biochem. Pharmacol. 7 (1961) 88Á
[37] A. Sparatore, F. Novelli, F. Sparatore, Quinolizidine derivatives
as ligands for sigma receptors, Med. Chem. Res. 11 (2002) 1Á11.
[38] H. Sugimoto, Y. Iimura, Y. Yamanishi, K. Yamatsu, Synthesis
and structureÁactivity relationships of acetylcholinesterase inhi-
/
95.
/
/
diidro-1,2,4-benzotriazin-3,3?-spirosteroidi d’interesse farmacolo-
/
gico, Farmaco, Ed. Sci. 35 (1980) 725Á734.
[20] A. Boido, F. Novelli, F. Savelli, F. Sparatore, S. Russo, W.
/
bitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperi-
dine hydro-chloride and related compounds, J. Med. Chem. 38
Filippelli, V. Susanna, E. Marmo, Preparazione e attivita` farm-
(1995) 4821Á4829.
/